Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Carboplatin in Mismatch repair-deficient Endometrial Carcinoma: NCT07108270 Clinical Landscape Report 2026
15 October 2026
NCT07108270 clinical landscape for Mismatch repair-deficient Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Cytarabine in Adult Acute Myeloblastic Leukemia: NCT07108530 Clinical Landscape Report 2026
15 October 2026
NCT07108530 clinical landscape for Adult Acute Myeloblastic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital) in Plasma Cell Leukemia: NCT07109323 Clinical Landscape Report 2026
15 October 2026
NCT07109323 clinical landscape for Plasma Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
mRNA-2808 in Multiple Myeloma: NCT07116616 Clinical Landscape Report 2026
15 October 2026
NCT07116616 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dostarlimab-gxly in Endometrial Carcinoma: NCT07115927 Clinical Landscape Report 2026
15 October 2026
NCT07115927 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT07117422 Clinical Landscape Report 2026
15 October 2026
NCT07117422 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LY-4257496 in Endometrial Carcinoma: NCT07114601 Clinical Landscape Report 2026
15 October 2026
NCT07114601 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RN-1201 in Multiple Myeloma: NCT07114432 Clinical Landscape Report 2026
15 October 2026
NCT07114432 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Idiopathic Inflammatory Myopathies: NCT07115745 Clinical Landscape Report 2026
15 October 2026
NCT07115745 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Tislelizumab in Urothelial Carcinoma of the Urinary Bladder: NCT07119996 Clinical Landscape Report 2026
15 October 2026
NCT07119996 clinical landscape for Urothelial Carcinoma of the Urinary Bladder: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Ocrelizumab in Multiple Sclerosis, Chronic Progressive: LBCTR2020030186 Clinical Landscape Report 2026
15 October 2026
LBCTR2020030186 clinical landscape for Multiple Sclerosis, Chronic Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
YTS-109 in Granulomatosis With Polyangiitis: NCT07123519 Clinical Landscape Report 2026
15 October 2026
NCT07123519 clinical landscape for Granulomatosis With Polyangiitis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…